Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28725398 | 0.86 | ALDH1A1 (0.64) | ALDH1A1PDK1TP53CYP3A4NLRP3 | |
| SCHEMBL813943 | 0.86 | — | — | |
| SCHEMBL2928403 | 0.86 | — | — | |
| SCHEMBL15440362 | 0.86 | — | — | |
| SCHEMBL7153238 | 0.84 | ALDH1A1 (0.44) | ALDH1A1TP53CYP3A4IRAK4MGLL | |
| SCHEMBL3806824 | 0.84 | ALDH1A1 (0.62) | ALDH1A1PDK1TP53CYP3A4NLRP3 | |
| Methane SCHEMBL6359894 | 0.84 | — | — | |
| SCHEMBL3803240 | 0.84 | ALDH1A1 (0.62) | ALDH1A1PDK1TP53CYP3A4NLRP3 | |
| SCHEMBL17522501 | 0.83 | ALDH1A1 (0.44) | ALDH1A1TP53CYP3A4IRAK4MGLL | |
| SCHEMBL2220998 | 0.83 | ALDH1A1 (0.49) | ALDH1A1PDK1TP53CYP3A4NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4217940-A | — | — | None | — | — | JP | disclosed |
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| JP-H04217940-A | ANTI-VIRAL COMPOUND | MERCK & CO INC | 1992-08-07 | — | — | JP | disclosed |
| US-4816447-A | HERPES VIRUS | MERCK & CO., INC. (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0074306-B1 | ANTI-VIRAL GUANINE DERIVATIVES | MERCK & CO. INC. (US) | 1988-06-01 | — | — | EP | disclosed |
| EP-0165164-A1 | Anti-viral compounds, their preparation and anti-viral compositions | MERCK & CO. INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| EP-0074306-A2 | Anti-viral guanine derivatives | MERCK & CO. INC. (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885PDK1 2353/4885TP53 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.